Abstract
The majority of variation in outcome following severe traumatic brain injury (TBI) remains unexplained by currently recognised prognostic factors, suggesting a contribution from unaccounted variables. One key candidate variable is neuroinflammation, including the generation of autoantibodies against brain specific antigens which have been described in some individuals following TBI. Here we hypothesised that autoantibody responses following TBI would differ between individuals, and would explain a proportion of outcome variance.
We developed a custom protein microarray to characterise the generation of autoantibodies to both central nervous system and systemic antigens in the acute-phase of TBI (within ten days of injury), and to determine their late (6-12 months) and long-term (6-13 years) persistence.
We identified two distinct patterns of response. The first was a broad response to the majority of antigens tested, predominantly IgM-mediated in the acute-phase, then IgG-dominant at late and long-term time-points. The second was of dominant responses to certain antigens, most frequently myelin-associated glycopeptide (MAG), which persisted for several months post-TBI but then subsequently resolved.
Exploratory analyses suggested that patients with a greater acute IgM response experienced worse outcomes than predicted. Furthermore, late persistence of anti-MAG IgM autoantibodies correlated with serum neurofilament light concentrations, suggesting an association with ongoing neurodegeneration over the first year post-injury.
Our results show that autoantibody production occurs in some individuals following TBI, can persist for many years, and may affect patient outcome. The complexity of responses mean that conventional approaches based on measuring responses to single antigenic targets may be misleading.
Competing Interest Statement
HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. AJC received honoraria and travel expenses from Genzyme [a Sanofi company] until September 2017. VFJN reports personal fees from Neurodiem, outside the submitted work. DKM reports grants, personal fees, and non-financial support from GlaxoSmithKline Ltd., grants, personal fees, and other from NeuroTrauma Sciences, grants and personal fees from Integra Life Sciences, personal fees from Pfizer Ltd., grants and personal fees from Lantmannen AB, from Calico Ltd., personal fees from Pressura Neuro Ltd., others from Cortirio Ltd., outside the submitted work. MT is the founder and CEO of Cambridge Protein Arrays Ltd., a company which performs antibody specificity profiling.
Funding Statement
EJN, AH, AJC, PJH and DKM are supported by the Medical Research Council (UK) within the framework of ERA-NET NEURON. ERZ is supported by the Ministero della Salute (Italy) within the framework of ERA-NET NEURON. DKM is supported by an NIHR Senior Investigator Award and European Union 7th Framework program (EC grant 602150). EJN is supported by the Intensive Care Society Young Investigator Award, Addenbrookes Charitable Trust Cambridge Clinical Research Fellowship and NIHR Brain Injury Healthcare Technology Co-operative Seedcorn funding. EPT acknowledges funding from Region Stockholm (ALF), the Swedish Brain Foundation (Hjarnfonden) and the Swedish Society for Medical Research (Svenska Sallskapet for Medicinsk Forskning). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), Centrum for Idrottsforskning (#P2019-0198), and the UK Dementia Research Institute at UCL. PJH is funded by the NIHR (Research Professorship and Cambridge BRC) and Royal College of Surgeons of England. JJ is funded by the Wellcome Trust (RG79413). VFJN is funded by an Academy of Medical Sciences / The Health Foundation Clinician Scientist Fellowship. HSM is supported by the Cambridge Trust and the Rosetrees Trust
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The studies described were approved either by the Cambridgeshire local research ethics committee (REC 97/290 and 13/EE/0119), or regional ethical board in Stockholm (#2005/1526/31/2).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this study are available upon request from the corresponding author.
Abbreviations
- BBB
- Blood-brain barrier
- CLDN5
- Claudin 5
- CNS
- Central nervous system
- COL5a2
- Collagen type 5 alpha 2 chain
- DAMP
- Danger-associated molecular pattern
- GFAP
- Glial fibrillary acidic protein
- GOS
- Glasgow Outcome Score
- GOSE
- Glasgow Outcome Score Extended
- Ig
- Immunoglobulin
- MAC
- Membrane attack complex
- MAG
- Myelin-associated glycopeptide
- MBP
- Myelin basic protein
- MFI
- Median fluorescence intensity
- NfL
- Neurofilament light
- SCI
- Spinal cord injury
- SELE
- E-selectin
- TBI
- Traumatic brain injury
- TJP-1
- Tight junction protein 1